Obesity - Pipeline Review, H2 2020

November 2020 | 640 pages | ID: O5F2BC0D9C1EN
Global Markets Direct

Abstracts

Obesity - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H2 2020, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.

Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 3, 23, 33, 4, 118, 48 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 54 and 13 molecules, respectively.

Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Obesity- Overview
Obesity- Therapeutics Development
Obesity- Therapeutics Assessment
Obesity- Companies Involved in Therapeutics Development
Obesity- Drug Profiles
Obesity- Dormant Projects
Obesity- Discontinued Products
Obesity- Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Obesity, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Obesity - Pipeline by Aardvark Therapeutics Inc, H2 2020
Obesity - Pipeline by Adare Pharma Solutions, H2 2020
Obesity - Pipeline by Adipo Therapeutics LLC, H2 2020
Obesity - Pipeline by Adocia SAS, H2 2020
Obesity - Pipeline by AgeX Therapeutics Inc, H2 2020
Obesity - Pipeline by Alla Chem LLC, H2 2020
Obesity - Pipeline by Altimmune Inc, H2 2020
Obesity - Pipeline by Amgen Inc, H2 2020
Obesity - Pipeline by Anagenesis Biotechnologies SAS, H2 2020
Obesity - Pipeline by Antag Therapeutics ApS, H2 2020
Obesity - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2020
Obesity - Pipeline by Applied Molecular Transport Inc, H2 2020
Obesity - Pipeline by AptamiR Therapeutics Inc, H2 2020
Obesity - Pipeline by Aptorum Group Ltd, H2 2020
Obesity - Pipeline by Armata Pharmaceuticals, H2 2020
Obesity - Pipeline by AstraZeneca Plc, H2 2020
Obesity - Pipeline by Athersys Inc, H2 2020
Obesity - Pipeline by Auris Medical Holding Ltd, H2 2020
Obesity - Pipeline by Betagenon AB, H2 2020
Obesity - Pipeline by BioRestorative Therapies Inc, H2 2020
Obesity - Pipeline by Biozeus Pharmaceutical SA, H2 2020
Obesity - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Obesity - Pipeline by Braasch Biotech LLC, H2 2020
Obesity - Pipeline by Bukwang Pharmaceutical Co Ltd, H2 2020
Obesity - Pipeline by Caliway Biopharmaceutics Co Ltd, H2 2020
Obesity - Pipeline by Callitas Therapeutics Inc, H2 2020
Obesity - Pipeline by Can-Fite BioPharma Ltd, H2 2020
Obesity - Pipeline by Carmot Therapeutics Inc, H2 2020
Obesity - Pipeline by Cellivery Therapeutics Inc, H2 2020
Obesity - Pipeline by Celon Pharma SA, H2 2020
Obesity - Pipeline by Centeer BioTherapeutics Ltd Co, H2 2020
Obesity - Dormant Projects, H2 2020
Obesity - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Obesity, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020